Summary of Significant Accounting Policies (Details 2)	12 Months Ended
	Jun. 30, 2013 USD ($) item	Jun. 30, 2012 USD ($)	Jun. 30, 2011 USD ($)	Jun. 30, 2013 EUR (€)	Jun. 30, 2012 EUR (€)
Inventory
Raw materials	$ 75,000	$ 129,000
Work in process	628,000	1,159,000
Total	703,000	1,288,000
Raw materials inventory write-downs	810,000	1,300,000
Minimum supply period based on firm, fixed orders and projections from collaborators, used to compute raw materials write downs	12 months
Rolling period of firm, fixed orders for conjugate that the company is required to manufacture	6 months
Rolling period of manufacturing projections for the quantity of conjugate the collaborator expects to need	12 months
Maximum period of firm, fixed orders and/or projections from collaborators considered for capitalizing inventory	12 months
Minimum supply period of raw materials that is not supported by firm, fixed orders and/or projections from collaborators considered to expense inventory	12 months
Charges to research and development expense related to raw material inventory identified as excess	798,000	748,000	1,700,000
Charges to research and development expense to write-down certain raw material inventory to its net realizable value	0	38,000	0
Other Accrued Liabilities
Accrued contract payments	2,406,000	1,773,000
Accrued clinical trial costs	1,849,000	865,000
Accrued professional services	678,000	677,000
Accrued employee benefits	411,000	351,000
Accrued public reporting charges	179,000	208,000
Other current accrued liabilities	526,000	715,000
Total	6,049,000	4,589,000
Financial Instruments and Concentration of Credit Risk
Number of financial institutions in the U.S. in which cash and cash equivalents are primarily maintained	3
Number of marketable securities held by entity	0
Net gains (losses) on forward contracts	197,000	(173,000)	189,000
Notional amounts of outstanding forward contracts	$ 57,000	$ 3,300,000		€ 41,000	€ 2,500,000